Acrivon Therapeutics
ACRV
ACRV
43 hedge funds and large institutions have $144M invested in Acrivon Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0.59% less ownership
Funds ownership: 68.98% → 68.39% (-0.59%)
26% less capital invested
Capital invested by funds: $196M → $144M (-$51.7M)
Holders
43
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$623K | |
| 2 | +$188K | |
| 3 | +$106K | |
| 4 |
State Street
Boston,
Massachusetts
|
+$69.8K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$64.1K |
Top Sellers
| 1 | -$746K | |
| 2 | -$492K | |
| 3 | -$92.5K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$52.6K |
| 5 |
BlackRock
New York
|
-$43.9K |